Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;174(10):921-932.
doi: 10.1111/bph.13695. Epub 2017 Jan 29.

Serelaxin in clinical development: past, present and future

Elaine Unemori  1
Affiliations
Review

Serelaxin in clinical development: past, present and future

Elaine Unemori. Br J Pharmacol. 2017 May.

Erratum in

  • Correction.
    [No authors listed] [No authors listed] Br J Pharmacol. 2017 Aug;174(15):2608. doi: 10.1111/bph.13911. Br J Pharmacol. 2017. PMID: 28718195 Free PMC article. No abstract available.

Abstract

The availability of highly purified recombinant human relaxin, serelaxin, has allowed clinical trials to be conducted in several indications and the elucidation of its pharmacology in human subjects. These studies have demonstrated that serelaxin has unique haemodynamic properties that are likely to contribute to organ protection and long-term outcome benefits in acute heart failure. Clinical observations support its consideration for therapeutic use in other patient populations, including those with chronic heart failure, coronary artery disease, portal hypertension and acute renal failure.

Linked articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors. Br J Pharmacol 172: 5744–5869. - PMC - PubMed
    1. Baccari MC, Bani D (2008). Relaxin and nitric oxide signalling. Curr Protein Pept Sci 9: 638–645. - PubMed
    1. Bani D (2008). Relaxin as a natural agent for vascular health. Vasc Health Risk Manag 4: 515–524. - PMC - PubMed
    1. Bathgate RA, Halls ML, Westhuizen ET, Callander GE, Kocan M, Summers RJ (2013). Relaxin family peptides and their receptors. Physiol Rev 93: 405–480. - PubMed
    1. Bennett RG, Heimann DG, Singh S, Simpson RL, Tuma DJ (2014). Relaxin decreases the severity of established hepatic fibrosis in mice. Liver Int 34: 416–426. - PMC - PubMed

MeSH terms